Actinium Pharmaceuticals (NYSEAM:ATNM) - Prezzo delle azioni, notizie e analisi

ATNM Panoramica delle azioni

ATNM analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 62.6% all'anno

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 0.3% all'anno per i prossimi 3 anni

Realizza un fatturato inferiore a 1 milione di dollari ( $81K )

Gli azionisti sono stati diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

+ 1 più rischio

Actinium Pharmaceuticals, Inc. Concorrenti

vTv Therapeutics

NasdaqCM:VTVT

US$37.0m

Entera Bio

NasdaqCM:ENTX

US$58.6m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Shattuck Labs

NasdaqGS:STTK

US$48.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Actinium Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.45
Massimo di 52 settimane	US$10.24
Minimo di 52 settimane	US$1.33
Beta	0.15
1Variazione di 1 mese	-13.69%
Variazione a 3 mesi	-27.14%
Variazione di 1 anno	-66.04%
3Variazione a 3 anni	-79.26%
Variazione a 5 anni	-83.08%
Variazione dall'IPO	-98.39%

Notizie e aggiornamenti recenti

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28

Rendimenti per gli azionisti

	ATNM	US Biotechs	US Mercato
7D	2.1%	4.0%	2.2%
1Y	-66.0%	18.3%	32.6%

Ritorno vs Industria: ATNM ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 18.3 % nell'ultimo anno.

Rendimento vs Mercato: ATNM ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.6 % nell'ultimo anno.

Volatilità dei prezzi

Is ATNM's price volatile compared to industry and market?
ATNM volatility
ATNM Average Weekly Movement	9.8%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: ATNM non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di ATNM è diminuita da 15% a 10% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	37	Sandesh Seth	www.actiniumpharma.com

Actinium Pharmaceuticals, Inc. sviluppa coniugati anticorpo-radiazioni e altre radioterapie mirate per migliorare i risultati delle persone che hanno fallito le terapie oncologiche esistenti. Il suo Iomab-B è un agente di induzione e condizionamento prima del trapianto di midollo osseo in pazienti con leucemia mieloide acuta recidivata e refrattaria (r/r AML). L'azienda si concentra sull'avanzamento dello sviluppo del candidato Actimab-A, un agente terapeutico che ha dimostrato un'attività potenziale nei pazienti affetti da LAM r/r.

Actinium Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Actinium Pharmaceuticals con la sua capitalizzazione di mercato?
ATNM statistiche fondamentali
Capitalizzazione di mercato	US$45.23m
Guadagni(TTM)	-US$40.91m
Ricavi(TTM)	US$81.00k

558.4x

Rapporto P/S

-1.1x

Rapporto P/E

ATNM è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ATNM Conto economico (TTM)
Ricavi	US$81.00k
Costo del fatturato	US$0
Profitto lordo	US$81.00k
Altre spese	US$41.00m
Guadagni	-US$40.91m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.31
Margine lordo	100.00%
Margine di profitto netto	-50,512.35%
Rapporto debito/patrimonio netto	0%

Come si è comportato ATNM nel lungo periodo?

Vedi performance storica e confronto

ATNM Panoramica delle azioni

Premi

Analisi del rischio

Actinium Pharmaceuticals, Inc. Concorrenti

NasdaqCM:VTVT

US$37.0m

NasdaqCM:ENTX

US$58.6m

NasdaqGS:FIXX

US$54.3m

NasdaqGS:STTK

US$48.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New major risk - Revenue and earnings growth

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Recent updates

New major risk - Revenue and earnings growth

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Price target decreased by 13% to US$24.78

Consensus EPS estimates fall by 10%

Price target decreased by 8.9% to US$27.41

Consensus revenue estimates decrease by 52%, EPS upgraded

Consensus revenue estimates increase by 13%

Price target increased by 15% to US$32.62

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Consensus revenue estimates fall by 16%

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to US$28.43

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Price target increased to US$27.23

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Price target decreased to US$24.04

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Consensus revenue estimates increase by 193%

Price target decreased to US$26.71

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023